- Home
- NWN vs HRMY Comparison
NWN vs HRMY Comparison
Compare NWN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWN
- HRMY
- Stock Information
- Founded
- NWN 1859
- HRMY 2017
- Country
- NWN United States
- HRMY United States
- Employees
- NWN N/A
- HRMY N/A
- Industry
- NWN Oil/Gas Transmission
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- NWN Utilities
- HRMY Health Care
- Exchange
- NWN Nasdaq
- HRMY Nasdaq
- Market Cap
- NWN 1.7B
- HRMY 2.0B
- IPO Year
- NWN N/A
- HRMY 2020
- Fundamental
- Price
- NWN $40.93
- HRMY $34.50
- Analyst Decision
- NWN Strong Buy
- HRMY Strong Buy
- Analyst Count
- NWN 3
- HRMY 8
- Target Price
- NWN $44.67
- HRMY $53.38
- AVG Volume (30 Days)
- NWN 289.4K
- HRMY 751.0K
- Earning Date
- NWN 05-06-2025
- HRMY 05-06-2025
- Dividend Yield
- NWN 4.78%
- HRMY N/A
- EPS Growth
- NWN 11.40
- HRMY 13.13
- EPS
- NWN 2.61
- HRMY 2.62
- Revenue
- NWN $1,213,808,000.00
- HRMY $744,852,000.00
- Revenue This Year
- NWN $18.65
- HRMY $20.35
- Revenue Next Year
- NWN $8.41
- HRMY $17.42
- P/E Ratio
- NWN $15.73
- HRMY $13.16
- Revenue Growth
- NWN 3.88
- HRMY 20.62
- 52 Week Low
- NWN $34.82
- HRMY $26.47
- 52 Week High
- NWN $44.38
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- NWN 43.75
- HRMY 58.40
- Support Level
- NWN $40.66
- HRMY $33.47
- Resistance Level
- NWN $41.52
- HRMY $35.35
- Average True Range (ATR)
- NWN 0.82
- HRMY 1.13
- MACD
- NWN -0.06
- HRMY -0.10
- Stochastic Oscillator
- NWN 48.80
- HRMY 42.41
About NWN Northwest Natural Holding Company
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in one reportable business segment, which is NW Natural's local gas distribution business and is referred to as the NGD segment. The company generates its revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.